Ren Goehrum - Biosyent CEO Chairman
| BIOYF Stock | USD 8.38 0.24 2.95% |
Insider
Ren Goehrum is CEO Chairman of Biosyent
| Age | 64 |
| Phone | 905 206 0013 |
| Web | https://www.biosyent.com |
Biosyent Management Efficiency
The company has return on total asset (ROA) of 0.1303 % which means that it generated a profit of $0.1303 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1938 %, meaning that it generated $0.1938 on every $100 dollars invested by stockholders. Biosyent's management efficiency ratios could be used to measure how well Biosyent manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 13 records | INSIDER Age | ||
| FACHM FAPWCA | Sanara Medtech | 52 | |
| Geri Plotzke | Pacific Health Care | 80 | |
| Bill Fitzgerald | Sanara Medtech | N/A | |
| Tricia Matteson | Sanara Medtech | N/A | |
| Callon Nichols | Sanara Medtech | N/A | |
| Donald Balzano | Pacific Health Care | 77 | |
| Kathy Torres | Pacific Health Care | 73 | |
| James Riva | Where Food Comes | N/A | |
| David Kim | Pacific Health Care | 50 | |
| Jane Fore | Sanara Medtech | N/A | |
| Jason Franco | Where Food Comes | N/A | |
| Sarah Haskins | Where Food Comes | N/A | |
| Carla Day | Sanara Medtech | N/A | |
Management Performance
| Return On Equity | 0.19 | |||
| Return On Asset | 0.13 |
Biosyent Leadership Team
Elected by the shareholders, the Biosyent's board of directors comprises two types of representatives: Biosyent inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biosyent. The board's role is to monitor Biosyent's management team and ensure that shareholders' interests are well served. Biosyent's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biosyent's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alfred DSouza, Advisor | ||
| Neelu Atwal, Director HR | ||
| Ren Goehrum, CEO Chairman | ||
| Robert March, CFO, Senior Vice President - Finance | ||
| Joost Mark, VP Devel |
Biosyent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Biosyent a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.19 | |||
| Return On Asset | 0.13 | |||
| Profit Margin | 0.22 % | |||
| Operating Margin | 0.29 % | |||
| Current Valuation | 45.49 M | |||
| Shares Outstanding | 12.1 M | |||
| Shares Owned By Insiders | 40.58 % | |||
| Shares Owned By Institutions | 1.30 % | |||
| Price To Earning | 23.21 X | |||
| Price To Book | 2.56 X |
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Other Information on Investing in Biosyent Pink Sheet
Biosyent financial ratios help investors to determine whether Biosyent Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biosyent with respect to the benefits of owning Biosyent security.